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Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USAa; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota,
USAb; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USAc; Program in Translational Immunovirology and Biodefense, Mayo Clinic,
Rochester, Minnesota, USAd; Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston Salem, North Carolina, USAe; Centers for Disease
Control and Prevention, Atlanta, Georgia, USAf; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USAg
Interindividual variations in vaccine-induced immune responses are in part due to host genetic polymorphisms in the human
leukocyte antigen (HLA) and other gene families. This study examined associations between HLA genotypes, haplotypes, and
homozygosity and protective antigen (PA)-specific cellular immune responses in healthy subjects following immunization with
Anthrax Vaccine Adsorbed (AVA). While limited associations were observed between individual HLA alleles or haplotypes and
variable lymphocyte proliferative (LP) responses to AVA, analyses of homozygosity supported the hypothesis of a “heterozygote
advantage.” Individuals who were homozygous for any HLA locus demonstrated significantly lower PA-specific LP than subjects
who were heterozygous at all eight loci (median stimulation indices [SI], 1.84 versus 2.95, P 0.009). Similarly, we found that
class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in
LP compared with heterozygosity at those three loci. Specifically, individuals who were homozygous at these loci had signifi-
cantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P 0.005), HLA-DQA1 (median
SI, 1.75 versus 2.11, P 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P 0.002) loci, respectively. Finally, homozygosity
at an increasing number (>4) of HLA loci was significantly correlated with a reduction in LP response (P< 0.001) in a dose-de-
pendent manner. Additional studies are needed to reproduce these findings and determine whether HLA-heterozygous individu-
als generate stronger cellular immune response to other virulence factors (Bacillus anthracis LF and EF) than HLA-homozygous
subjects.
Bacillus anthracis is a Gram-positive, spore-forming pathogenthat acts through toxin production and infects both humans
and animals. The organism’s virulence factors include protective
antigen (PA), lethal factor (LF), and edema factor (EF) (1). PA is
divided into four different functional domains, with toxin-neu-
tralizing antibody (Ab) epitopes mapping to specific domain 4
(residues 596 to 735) (1). PA is known to bind to a receptor on the
cell surface and mediate the entry of both LF and EF into the cell.
Recombinant PA-based vaccines have demonstrated protective
properties in several animal models, including rhesus macaques,
against B. anthracis subcutaneous (SQ) and aerosol challenges (2–
4). Vaccines based on recombinant PA (rPA) are being considered
as novel anthrax vaccine candidates (5, 6).
Anthrax Vaccine Adsorbed (AVA; Biothrax, Lansing, MI) was
licensed in 1970 and is produced from an avirulent strain of B.
anthracis. Given the role of PA in the pathogenesis of clinical dis-
ease, levels of antibody (Ab) to anthrax PA (AbPA) in humans
have been generally accepted as the primary measure of immuno-
genicity following vaccination and/or exposure (3). While there is
limited information available on the development of cell-medi-
ated immunity (CMI) after AVA vaccination, data from experi-
mental animal models suggest that PA-specific humoral responses
are important for protection against anthrax disease (7, 8).
The Centers for Disease Control and Prevention (CDC)
funded a multicenter, double-blind, placebo-controlled, random-
ized clinical trial that tested multiple regimens of AVA (clinical-
trials.gov identifier NCT00119067, here labeled AVA000) (9).
Prior to AVA000, the licensed regimen for AVA consisted of SQ
administration of six primary doses followed by annual booster
doses. An interim analysis of the AVA000 data led the Food and
Drug Administration (FDA) to approve a change to the licensed
regimen, including a dose reduction from six to five doses and a
switch to intramuscular (IM) administration (10).
Differences in the immune responses to AVA, particularly be-
tween individuals of European and African ancestry, have sug-
gested a role for host genetic factors (9, 11, 12). Among the most
likely candidate genes are the highly polymorphic human leuko-
cyte antigen (HLA) loci on chromosome 6 with alleles that are
known to bind a repertoire of naturally processed peptides pre-
sented to T cells (13). On the basis of the AVA000 data, Pajewski et
al. (14) examined HLA haplotype associations with various anti-
body responses to AVA, finding significant associations between
several DRB1-DQA1-DQB1 haplotypes (*15:01-*01:02-*06:02,
*01:01-*01:01-*05:01, and *01:02-*01:01-*05:01) and lower pro-
duction of AbPA (14). The objective of the present study was to
further examine HLA polymorphisms within the specific context
of PA-induced cellular immunity. To this end, we hypothesized
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that polymorphisms within the HLA genes are associated with
cellular immune responses to AVA. We specifically sought to
study the role of HLA alleles, haplotypes, and homozygosity in
lymphoproliferative responses to PA following vaccination with
AVA.
MATERIALS AND METHODS
Study subjects. Details of AVA000 have been published elsewhere (9, 14).
In brief, 1,564 healthy subjects between 18 and 61 years of age were en-
rolled at five sites, including the Mayo Clinic (Rochester, MN); Walter
Reed Army Institute of Research (Silver Spring, MD); Baylor College of
Medicine (Houston, TX); Emory University School of Medicine (Atlanta,
GA); and the University of Alabama at Birmingham (Birmingham, AL).
We examined a cross-sectional convenience sample of 331 AVA000 par-
ticipants, measuring the immune response approximately 1 month fol-
lowing the 6-month vaccination (week 30), which corresponds to either
the third or fourth dose of AVA depending on the study arm within which
the subject participated. Subjects in this convenience sample agreed to
participate in a substudy of HLA and lymphocyte proliferation requiring
additional blood draws. Of these 331 subjects, 56 were randomly assigned
to the saline placebo arm and thus were excluded from the present anal-
yses. Table 1 lists demographic characteristics for the remaining 275 sub-
jects as well as their distribution across the five active treatment arms. The
Institutional Review Boards of the Mayo Clinic, CDC, Walter Reed Army
Institute of Research, Baylor College of Medicine, Emory University
School of Medicine, and University of Alabama at Birmingham approved
the study, and written informed consent from each subject was obtained
before enrollment. The present study includes only those volunteers who
expressly approved (with written consent) the use of their samples and
data for further research.
Lymphocyte proliferation (LP) to rPA of Bacillus anthracis. Blood
samples were collected from each subject at week 30 (1 month postvac-
cination) into CPT Vacutainer tubes. Peripheral blood mononuclear cells
(PBMCs) were harvested as previously described (15). PBMCs were
plated in quadruplicate into 96-well round bottom microtiter plates con-
taining 200 l of either cell culture media alone or media containing 1.25
g/ml recombinant protective antigen (rPA) (BEI Resources, Manassas,
VA). The positive control was phytohemagglutinin (PHA; 10 g/ml).
PBMCs were incubated for 96 h at 37°C in a 5% CO2 atmosphere. Cul-
tures were then pulsed with 20 l of a 50 Ci/ml [3H]thymidine solution
and incubated for 18 h at 37°C in a 5% CO2 atmosphere. Cells were
harvested onto filter discs (Fisher, Pittsburgh, PA) and counted on a Pack-
ard scintillation counter (Packard, Meriden, CT). Stimulation indices (SI)
were assessed as the quotient of mean counts per minute of PA-stimulated
cells divided by the mean counts per minute of unstimulated cells. A
positive lymphoproliferative response was defined empirically as the
mean baseline SI across all enrolled individuals (1.1) plus twice the stan-
dard deviation (0.53), or 2.16.
HLA genotyping. HLA genotyping was carried out with high-resolu-
tion A-SSP, C-SSP, DQA-SSP, DQB1-SSP, DPA1-SSP, and DPB1-SSP
Unitray typing assays (Invitrogen), as previously described (16, 17). Class
I HLA-B and class II DRB1 locus typing was performed using high-reso-
lution automated reference strand conformation analysis (RSCA) and
SSP Unitray typing kits (Invitrogen), as previously described (17).
Statistical methods. Our statistical approach and the description of
the statistical analyses and methods are nearly identical to what we have
previously published (16, 18–22). Data were descriptively summarized
using frequencies and percentages for all categorical variables and medi-
ans and interquartile ranges (IQR) for all continuous variables. Associa-
tions of SI values with demographic and clinical variables of interest were
assessed using analysis of variance methods.
TABLE 1 Demographic characteristics of subjects from the AVA000 clinical triala
Parameter Value n Mean SI SD Median SI Q1 Q3 P valueb
Overall 275 5.5 8.3 1.9 1.2 6.1
Age group (yr) 30 63 6.6 8.2 2.9 1.3 8.5 0.025
30–39 64 5.6 8.7 1.9 1.2 4.1
40–49 83 6.0 8.8 2.1 1.2 7.4
50–62 65 3.7 7.1 1.5 1.0 3.6
Sex Female 139 5.9 8.6 2.0 1.2 6.8 0.433
Male 136 5.1 7.9 1.9 1.2 5.5
Race Other race/ethnicity 57 4.9 7.1 1.9 1.2 5.1 0.555
White 218 5.7 8.5 2.0 1.2 6.2
Clinical site name Baylor 62 4.3 5.0 2.4 1.3 5.1 0.001
Emory 43 11.1 12.0 6.7 2.2 15.4
Mayo 40 8.6 11.3 2.5 1.3 11.0
UAB 57 4.2 6.8 1.5 1.1 2.6
WRAIR 73 2.6 3.7 1.5 1.0 2.7
Arm/group TRT-4IM (3IM) 56 4.5 6.7 1.4 1.1 4.8 0.600
TRT-5IM (3IM) 55 6.2 9.3 2.4 1.1 5.5
TRT-7IM (3IM) 53 6.2 9.2 1.9 1.3 7.4
TRT-8IM (4IM) 56 4.9 7.0 2.1 1.2 5.3
TRT-8SQ (4SQ) 55 5.9 8.9 1.9 1.2 6.7
a See Marano et al. for a description of the study groups (9). Prior to sampling at week 30, the 3IM arms (TRT-4IM, TRT-5IM, and TRT-7IM) received 3 intramuscular (IM) doses
of AVA (0.5 ml) at 0 and 4 weeks and 6 months with 0.5 ml placebo at 2 weeks; the 4IM arm (TRT-8IM) received 4 IM doses of AVA (0.5 ml) at 0, 2, and 4 weeks and 6 months;
and the 4SQ (TRT-8SQ) arm received 4 doses SQ AVA 0.5 ml at 0, 2, and 4 weeks and 6 months. Q1 and Q3, the first and third quartiles, respectively. SQ, subcutaneously; TRT,
treatment; SI, stimulation index; Baylor, Baylor College of Medicine; Emory, Emory University School of Medicine; Mayo, Mayo Clinic; UAB, University of Alabama at
Birmingham; WRAIR, Walter Reed Army Institute of Research.
b Data represent the results of analysis of variance using log-transformed SI values.
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Separate HLA allelic analyses were carried out for each locus. Alleles
were grouped by HLA genotype, and descriptive summaries for the mea-
sures of SI were first obtained using medians and interquartile ranges.
Individuals contributed two observations to these descriptive summaries:
one for each allele. Associations between HLA alleles and SI were then
formally evaluated using linear regression models. In these models, re-
gression variables for each allele were coded 0, 1, or 2, according to the
number of copies of the allele that a subject carried. Separate analyses were
carried out using both four-digit and two-digit allele types. Differences in
SI among all alleles of each HLA locus were first assessed globally by
inclusion of all but one of the ordinal allele variables in a multivariable
linear model and simultaneously testing the significance of the entire set
of alleles from that HLA locus. Following these global tests, we examined
individual allele associations with SI. Each allele was tested individually by
inclusion of only the variable corresponding to that allele in separate
linear models, effectively comparing the effect of the allele of interest on SI
relative to those of all other alleles combined. These series of tests were
performed in the spirit of Fisher’s protected least-significant-difference
test; individual allele associations were not considered statistically signif-
icant in the absence of locus-specific global significance.
We next examined associations between SI and HLA haplotypes. Two
sets of haplotypes were considered: one for the three class I loci (A, B, and
C) and one for the five class II loci (DRB1, DQA1, DQB1, DPA1, and
DPB1). Because each individual’s linkage phase is unknown, there may be
multiple pairs of haplotypes that are consistent with the observed HLA
alleles. Posterior probabilities of all possible haplotypes for an individual,
conditional on the observed genotypes, were estimated using an expecta-
tion-maximization (EM) algorithm similar to the method outlined by
Schaid et al. (23). Haplotype design variables were then created using
these posterior probabilities. As with the allelic variables, values for each
haplotype variable ranged from 0 to 2 and can be considered to be the
estimated number of that haplotype carried by the individual after ac-
counting for phase ambiguity. We retained only those haplotypes occur-
ring at least five times in the cohort, pooling all lower frequency haplo-
types into an “other” category. Formal analyses then proceeded with these
design variables, using the same two-step approach as was used with the
allelic analyses, by first assessing associations on a global level and then
proceeding with individual haplotype tests only in the presence of a sta-
tistically significant global test. Due to phase ambiguity, haplotype-spe-
cific descriptive summaries using medians and interquartile ranges could
not be obtained using the same approach we applied for individual alleles.
Thus, descriptive summaries were represented using the t-statistics ob-
tained from the linear regression analyses. Although not displayed using
the original units of measurement, these t-statistics can still be used to
assess the magnitude and direction of the haplotype effect since negative
values correspond to haplotype-specific decreases in SI and positive values
correspond to increases in SI.
We also compared measures of SI in homozygous versus heterozygous
individuals using linear regression techniques. Variables representing lo-
cus-specific homozygosity status were created for each of the eight avail-
able loci. We first fit a separate model for each of the HLA loci. We then
created a variable indicating whether a subject was homozygous for at
least one of the loci and assessed its relationship with immune response.
We then calculated a homozygosity count for each subject. Values of this
count could range from 0 to 8, depending on the number of loci for which
the subject was homozygous. However, due to the sparseness of the data,
individuals homozygous for five or more loci were grouped with those
homozygous for four loci. Using this count variable, we assessed the pos-
sible dose-response relationship between homozygosity and immune re-
sponse by fitting the count as a simple ordinal variable.
All formal linear regression analyses described above were adjusted for
the following set of potential confounding variables: age at enrollment in
years (categorized as 30, 30 to 39, 40 to 49, or 60 to 62); gender; race
(Caucasian or non-Caucasian); study site; and randomized treatment
arm. Due to data skewness, all formal regression analyses were carried out
using log-transformed SI values. All statistical tests were two sided, and all
analyses were carried out using the SAS (SAS Institute, Inc., Cary, NC) and
S-Plus (Insightful, Inc., Seattle, WA) software systems.
RESULTS
Subject sample demographics. Of the 331 subjects enrolled into
the HLA and Immune Correlates of Protection AVA substudies,
275 subjects who received AVA by the SQ or IM route had both
HLA typing and cellular immunity (LP) data available. These 275
subjects consisted of healthy individuals between 30 and 62 years
of age and were the focus of this study. The majority of the subjects
were Caucasian (n  218), and 136 were male (Table 1). As de-
scribed by Marano et al. (9), these subjects received AVA by the IM
(4IM, 5IM, 7IM, and 8IM) or SQ (8SQ) route. There were statis-
tically significant differences in LP across the age of study subjects
and across the number of subjects enrolled at each clinical site.
However, there were no differences in lymphoproliferative re-
sponses with regard to sex, race, or AVA vaccination regimen. The
overall median SI for 275 study subjects, assessed by stimulation of
PBMCs with PA, was 1.9 (IQR, 1.2 to 6.1). We did not find evi-
dence of a significant association between age and HLA homozy-
gosity.
Associations between HLA alleles and haplotypes and lym-
phocyte proliferative response. We did not identify significant
relationships between either class I or class II alleles and lym-
phoproliferative responses (Table 2), as no single HLA locus dem-
onstrated a significant (P  0.05) global association. The locus
with the smallest global P value was HLA class II DQB1 (P 
0.058). Two specific alleles, DQB1*06:04 (median SI, 5.03) and
DQB1*05:02 (median SI, 4.15), demonstrated higher LP re-
sponses to PA. However, these potential allelic effects must be
interpreted with caution due to the lack of a significant global
effect and the relatively small sample size; the results from these
analyses did not conclusively demonstrate that any HLA alleles
were significantly associated with LP. Separate analyses were car-
ried out to investigate whether associations between responses to
PA and HLA haplotypes were present. The global tests of associa-
tion for class I (P value  0.729) or class II (P value  0.381)
haplotypes with LP responses to PA did not reach statistical sig-
nificance.
HLA homozygosity and lymphocyte proliferative response.
AVA-vaccinated subjects who were homozygous at any HLA locus
demonstrated significantly lower PA-specific lymphoprolifera-
tion than those subjects who were heterozygous at all eight loci
(median SI, 1.84 versus 2.95, P  0.009) (Table 3). When we
examined the association between homozygosity at increasing
numbers of HLA loci and cell-mediated reactivity to PA, we dis-
covered that increasing numbers of homozygous HLA loci were
significantly associated with reductions in LP response (P 
0.001) in a dose-dependent manner. When we examined homozy-
gosity effects for specific loci, we found that subjects who were
homozygous at HLA-A, DQA1, and DQB1 loci (based on the
four-digit allele types) had significantly lower PA-specific lym-
phoproliferation than subjects who were heterozygous at A (me-
dian SI, 1.48 versus 2.13, P  0.005), DQA1 (median SI, 1.75
versus 2.11, P  0.007), and DQB1 (median SI, 1.48 versus 2.13,
P  0.002) loci, respectively. In addition, LP responses to PA in
subjects homozygous for the HLA-C and DPB1 loci were margin-
ally significantly lower than in subjects who were heterozygous for
HLA-C (median SI, 1.51 versus 2.08, P 0.067) and DPB1 (me-
Ovsyannikova et al.
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dian SI, 1.62 versus 2.11, P 0.097). Similar results were achieved
based on the two-digit allele types.
We also evaluated the association between HLA homozygosity
and humoral PA-specific antibody responses to anthrax vaccina-
tion. While those who are homozygous appear to have slightly
lower AbPA responses than those who are heterozygous, these
differences are small and we do not have adequate statistical power
to confirm or refute the presence of a significant association (see
Table S1 in the supplemental material).
DISCUSSION
It is well recognized that interindividual variations exist in im-
mune responses to vaccines and that these variations are in part
due to host genetic polymorphisms in HLA and other genes (24).
Each HLA molecule binds a distinct set of self- and antigenic pep-
tides that can trigger CMI responses and influence humoral re-
sponses through T helper cells. HLA-homozygous individuals
logically present a more limited range of peptides than heterozy-
gous individuals at the same HLA loci. Presentation of a narrower
range of peptides may lead to diminished CD4 and CD8 T cell
recognition and in turn may elicit weaker antigen-specific T cell
responses. However, diminished T cell response can also be a re-
sult of T cell-mediated defects or allelic polymorphisms in genes
other than HLA (25, 26).
The goal of this study was to examine associations between LP
responses to PA following AVA vaccination and HLA genotypes,
haplotypes, and homozygosity. We did not find significant asso-
ciations of individual HLA alleles or haplotypes with interindi-
vidual variations in cellular immune responses to AVA. We did,
however, find statistically significant associations with overall ho-
mozygosity and homozygosity at one class I locus and at two class
II loci whose alleles are in tight linkage disequilibrium (LD). We
found that class I (A) and class II (DQA1 and DQB1) homozygos-
ity (as determined by four-digit molecular HLA typing) was sig-
nificantly associated with an overall decrease in LP response com-
pared with class I (A) and class II (DQA1 and DQB1)
heterozygosity. Furthermore, according to the results of the two-
digit molecular HLA typing, class I (A and B) and class II (DRB1,
DQA1, and DPB1) homozygosity was associated with decreased
PA-specific lymphoproliferation. The linkage between decreased
lymphocyte proliferation and HLA homozygosity suggests that
HLA-heterozygous individuals generate stronger CMI responses
to anthrax PA than homozygous subjects who carry these specific
alleles. It is possible that differences in the repertoire of PA-de-
rived epitope presentation are likely the basis for these associa-
tions between HLA homozygosity and decreased LP response.
However, the biological significance of these results and whether
these findings can be generalized to other B. anthracis virulence
factors (LF and EF) are unclear. Further, based on comparisons
with a subset of European-American subjects in this study with
available genome-wide genotyping on the Affymetrix 6.0 array
(12), we did not find any association between heterozygosity at the
HLA loci and genome-wide heterozygosity (data not shown).
HLA class II alleles are encoded by DR, DQ, and DP polymor-
phic genes, and many class II alleles have been found to be impor-
tant immunogenetic markers for both vaccine-induced viral and
bacterial immune responses (14, 27). A relationship between spe-
cific DRB1-DQA1-DQB1 haplotypes and a significantly lower
AbPA humoral response to AVA has been previously demon-
strated (14). In particular, that study found an association be-
tween the DRB1*01:02-DQA1*01:01-DQB1*05:01 haplotype and
significantly lower AbPA levels following AVA (14). Our study
found that A, DQA1, and DQB1 homozygosity (at four-digit mo-
lecular resolution) and A, B, DRB1, and DQA1 homozygosity (at
two-digit molecular resolution) are significantly associated with
diminished PA-specific lymphoproliferation. This suggests that
AVA vaccination induces a dominant HLA-restricted immune re-
sponse to PA antigens and that HLA homozygosity at both class I
TABLE 2 HLA allelic associations with anthrax protective antigen-specific lymphoproliferative responses
HLA locus Allele n Median SI Q1 Q3 Allele P value Global P valuea
A *6801 15 1.28 1.09 2.23 0.004 0.223
B *3503 8 1.43 1.16 3.33 0.029 0.553
*4403 39 2.58 1.45 7.36 0.046
C *0102 16 7.01 1.80 13.21 0.005 0.206
DPA1 None 0.809
DPB1 *0201 81 2.71 1.34 7.11 0.085 0.258
*1001 9 4.53 2.33 10.04 0.063
*1501 5 8.49 1.66 17.08 0.024
DQA1 None 0.565
DQB1 *0502 10 4.15 2.02 8.59 0.047 0.058
*0604 19 5.03 1.42 11.94 0.011
DRB1 *0102 21 1.80 1.31 2.58 0.092 0.133
*0407 6 0.89 0.62 1.25 0.059
*1101 39 4.05 1.46 7.84 0.009
*1363 5 17.08 1.42 26.09 0.086
a Data represent the results of linear regression analysis. P values for SI levels were determined on the basis of log transformation. Analyses were adjusted for gender, age groups,
study site, route of immunization, time between vaccinations, time between blood draw procedures, and number of AVA doses. Alleles corresponding to P 0.10 are included.
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and class II antigen presentation pathways potentially diminishes
an individual’s ability to generate strong cellular immune re-
sponses to PA antigens. The possible use of PA-derived epitopes
for DRB1*04:01 and DRB1*07:01 and class II tetramers as tools to
examine PA-specific Th2 CD4 cellular immune responses in
AVA vaccinees was recently illustrated (28). This is of great inter-
est in light of the potential use of HLA tetramers as tools to mon-
itor T cell responses in vaccinated individuals and for design of
subunit and peptide vaccine candidates against B. anthracis and
other pathogens (29, 30).
Narrower restriction of immune responses in HLA-homozy-
gous individuals (the long recognized “homozygote disadvan-
tage”) has been reported for hepatitis C virus (31), human immu-
nodeficiency virus (HIV) (32, 33), hepatitis B virus (HBV) (34),
and herpes simplex virus type 1 (HSV-1) (35) infections. These
studies clearly demonstrated that HLA homozygosity may be a
susceptibility factor for infection (36). Studies correlating HLA
homozygosity with the immune responses to HBV, measles virus,
and mumps virus vaccines have demonstrated similar results (22,
33, 37). For example, HLA homozygosity has been correlated with
TABLE 3 HLA homozygosity associations with lymphocyte proliferation to anthrax protective antigen
HLA locus parameter Category or level n Median SI Q1 Q3 P valuea
4 digit
A Heterozygous 231 2.13 1.24 6.78 0.005
Homozygous 44 1.48 1.03 2.28
B Heterozygous 258 2.08 1.24 6.40 0.105
Homozygous 17 1.17 0.98 1.65
C Heterozygous 250 2.08 1.24 6.40 0.067
Homozygous 25 1.51 1.07 2.28
DRB1 Heterozygous 249 1.94 1.22 6.23 0.295
Homozygous 26 1.84 1.03 4.53
DPA1 Heterozygous 102 2.03 1.17 7.38 0.342
Homozygous 173 1.90 1.19 4.80
DQA1 Heterozygous 225 2.11 1.25 6.78 0.007
Homozygous 50 1.75 1.04 2.64
DQB1 Heterozygous 233 2.13 1.25 6.92 0.002
Homozygous 42 1.48 1.01 2.23
DPB1 Heterozygous 213 2.11 1.21 6.76 0.097
Homozygous 62 1.62 1.12 3.78
Any locus Heterozygous 70 2.95 1.30 9.56 0.009
Homozygous 205 1.84 1.16 4.49
No. homozygous 0 70 2.95 1.30 9.56 <0.001
1 81 1.89 1.22 5.05
2 69 2.13 1.25 6.40
3 27 1.69 1.02 3.62
4 28 1.40 1.02 2.08
2 digit
A Heterozygous 230 2.13 1.24 6.78 0.006
Homozygous 45 1.51 1.04 2.33
B Heterozygous 253 2.11 1.25 6.68 0.017
Homozygous 22 1.20 0.96 1.65
C Heterozygous 237 2.02 1.22 6.28 0.343
Homozygous 38 1.67 1.14 4.69
DRB1 Heterozygous 232 2.11 1.25 6.74 0.020
Homozygous 43 1.57 1.04 2.64
DPA1 Heterozygous 90 1.86 1.13 6.92 0.669
Homozygous 185 1.94 1.22 5.05
DQA1 Heterozygous 188 2.29 1.27 7.20 0.017
Homozygous 87 1.78 1.06 3.62
DPB1 Heterozygous 187 2.12 1.22 7.29 0.059
Homozygous 88 1.69 1.11 3.60
DQB1 Heterozygous 184 1.97 1.24 5.89 0.456
Homozygous 91 1.86 1.12 6.06
Any locus Heterozygous 44 2.34 1.15 6.73 0.901
Homozygous 231 1.90 1.19 5.87
No. homozygous 0 44 2.34 1.15 6.73 0.006
1 57 3.10 1.28 11.23
2 80 2.03 1.38 4.53
3 40 1.89 1.25 7.07
4 54 1.38 1.02 2.36
a P values for SI levels were determined on the basis of log transformation. Statistically significant P values are in bold type (P 0.05). IQR, interquartile range. Linear regression
analysis was adjusted for gender, age groups, study site, route of immunization, time between vaccinations, time between blood draw procedures, and number of AVA doses.
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nonresponse to hepatitis B (HBsAg) vaccine in individuals ho-
mozygous for the haplotype HLA-B8, SC01, DR3 (38). These ob-
servations, together with our current findings, indicate that HLA
homozygosity may adversely influence immune responses to bac-
terial as well as viral vaccines.
Likewise, our previous work with measles virus vaccine dem-
onstrated significant associations of overall and specific homozy-
gosity at HLA loci with lower levels of measles virus IgG antibodies
after one dose of vaccine (37). Homozygosity at an increased
number of HLA loci, as well as homozygosity at the class I A locus,
has been correlated with both decreased mumps virus vaccine-
specific antibody levels and lymphoproliferation (22). However,
two doses of measles virus vaccination appear to diminish this
“homozygote disadvantage” despite HLA homozygosity status at
least for measles virus humoral Ab responses (22), suggesting that
additional vaccine doses may overcome this genetic disadvantage
(39). Similarly, homozygosity within the DPB1 locus showed no
disadvantage for both rubella virus-induced IgG antibody levels
after two doses of rubella vaccine (40). This dampening phenom-
enon may imply that additional anthrax immunizations may be
necessary to induce higher levels of immunity in individuals who
are homozygous for specific HLA alleles.
This is the first report of the effect of HLA genotypes and HLA
homozygosity on cell-mediated (lymphoproliferative) immune
responses following AVA vaccination. The strengths of our study
included the use of subjects selected from a multicenter, random-
ized clinical trial that tested multiple schedules of the licensed
AVA vaccine. Our study also used high-resolution HLA class I and
class II genotyping using PCR-based technologies, including au-
tomated RSCA and sequence-based typing. Limitations of the
study included a somewhat small sample size and limited racial
diversity of our study sample, since 80% of the study subjects were
Caucasian. Replication of our findings in African-Americans and
other racial groups will be required to clarify the role of homozy-
gosity of HLA alleles in AVA-induced immunity in different races
and ethnicities. Additionally, lymphocyte proliferation testing
was used as a proxy for PA-specific CMI. Due to the long (43-
month) follow-up of the AVA000 study, a traditional, accurate,
and sensitive in vitro assay was utilized to assess the functional
capacity of T lymphocytes to respond to the major component of
the AVA vaccine. However, these data on recall lymphoprolifera-
tive response to rPA in our AVA-vaccinated subjects do not rep-
resent a true “CMI” correlate of protection induced by vaccina-
tion (41).
The central role of cellular immune responses in postvaccina-
tion protection from anthrax was recently demonstrated in a
study of AVA-induced long-term protection in rhesus macaques
(15). A striking aspect of those data was that a three-dose intra-
muscular AVA priming series elicited persistent production of
functional PA-specific gamma interferon (IFN-)- and interleu-
kin-4 (IL-4)-producing T cells and of memory B cells as long as
50.5 months postvaccination when serum AbPA titers were low or
undetectable. Irrespective of the humoral antibody titers at the
time of infection, nonhuman primates were able to mount a ro-
bust and protective anamnestic response after aerosol exposure to
B. anthracis. Analogous CMI profiles and anamnestic anti-PA IgG
responses were also evident in human AVA vaccinees (42).
While we found a strong recall lymphoproliferative response to
rPA in our AVA-vaccinated subjects, Ingram et al. found signifi-
cant elevations of T cell IFN- release in response to B. anthracis
LF (domain IV) but not PA as measured by enzyme-linked immu-
nosorbent spot (ELISpot) assays in United Kingdom-licensed An-
thrax Vaccine Precipitated (AVP)-vaccinated subjects (29). Nat-
urally infected subjects demonstrate strong CD4T cell responses
to both PA and LF (29). Those authors theorized that vaccination
skewed the immune response toward a Th2 response, an idea that
was supported by the limited response in IL-5 and IL-13 and con-
trasted with the response seen in the cutaneous anthrax patients
(29). It is not known if AVA vaccination similarly biases toward a
Th2 response or what the lymphoproliferative response would be
to LF.
In conclusion, this report illustrates HLA gene contribution to
host immunity associated with variable cellular immune re-
sponses to AVA. This information is likely to help to identify an-
tigenic protective peptides within the PA of B. anthracis and influ-
ence future anthrax vaccine design. New anthrax vaccine
candidates that offer protection and result in long-lasting immu-
nity are needed. Additional studies are also necessary to replicate
these findings and determine whether HLA-heterozygous individ-
uals generate a stronger cellular immune response to other viru-
lence factors (B. anthracisLF and EF) than HLA-homozygous sub-
jects.
ACKNOWLEDGMENTS
This study was funded by the CDC Anthrax Vaccine Research Program
(AVRP), DHHS CDC Contract no. 200-2000-10065 and 200-2000-10065.
R.A.K. was supported in part by contract N01-AI40068 from the National
Institute of Allergy and Infectious Diseases.
We gratefully acknowledge the AVRP principal investigators: Janiine
Babcock (Walter Reed Army Institute of Research), Wendy Keitel (Baylor
College of Medicine), Harry Keyserling (Emory University School of
Medicine), Scott Parker (University of Alabama at Birmingham), and
Jennifer Wright (CDC). We also acknowledge the contributions of Nina
Marano, former CDC principal investigator for the CDC Anthrax Vaccine
Research Program (AVRP). We thank the Mayo Clinic Vaccine Research
Group staff and subjects who participated in this study. We also thank
Norman Pinsky, Megan O’Byrne, Diane Grill, and Caroline Vitse (Mayo
Clinic) and Shetul Shah, Charles Rose, and Brian D. Plikaytis (NCIRD,
CDC) for their help with this study.
G.A.P. has served as a consultant to Emergent Biosolutions Inc. (Rock-
ville, MD). I.G.O, V.S.P., R.A.V., N.M.P., C.P.Q., R.A.K., and R.M.J. de-
clare that we have no conflicts of interest.
The findings and conclusions in this report are ours and do not nec-
essarily represent the views of the Centers for Disease Control and Pre-
vention. The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National Institutes of
Health.
These activities have been reviewed by the Mayo Clinic Conflict of
Interest Review Board and are conducted in compliance with Mayo Clinic
Conflict of Interest policies. This research has been reviewed by the Mayo
Clinic Conflict of Interest Review Board and was conducted in compli-
ance with Mayo Clinic Conflict of Interest policies.
REFERENCES
1. Brossier F, Weber-Levy M, Mock M, Sirard JC. 2000. Role of toxin
functional domains in anthrax pathogenesis. Infect. Immun. 68:1781–
1786.
2. Cybulski RJ, Jr, Sanz P, O’Brien AD. 2009. Anthrax vaccination strate-
gies. Mol. Aspects Med. 30:490 –502.
3. Williamson ED, Hodgson I, Walker NJ, Topping AW, Duchars MG,
Mott JM, Estep J, Lebutt C, Flick-Smith HC, Jones HE, Li H, Quinn CP.
2005. Immunogenicity of recombinant protective antigen and efficacy
against aerosol challenge with anthrax. Infect. Immun. 73:5978 –5987.
4. Little SF, Ivins BE, Webster WM, Fellows PF, Pitt ML, Norris SL,
HLA and Anthrax Vaccine Adsorbed Cellular Immunity
July 2013 Volume 81 Number 7 iai.asm.org 2589
 
 
Andrews GP. 2006. Duration of protection of rabbits after vaccination
with Bacillus anthracis recombinant protective antigen vaccine. Vaccine
24:2530 –2536.
5. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner
J, Deans L, Gurwith M. 2006. Immunogenicity and tolerance of ascend-
ing doses of a recombinant protective antigen (rPA102) anthrax vaccine: a
randomized, double-blinded, controlled, multicenter trial. Vaccine 24:
5950 –5959.
6. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L,
Kotloff KL. 2007. Safety, reactogenicity and immunogenicity of a recom-
binant protective antigen anthrax vaccine given to healthy adults. Hum.
Vaccin. 3:205–211.
7. Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB,
Taylor DN. 2008. Serum IgG antibody response to the protective antigen
(PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA)
among U. S. military personnel. Vaccine 26:869 – 873.
8. Grabenstein JD. 2003. Anthrax vaccine: a review, p 713–730. In Poland
GA (ed), Immunology and allergy clinics of North America: vaccines in
the 21st century. WB Saunder Company, Philadelphia, PA.
9. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin
SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W,
El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox
SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP.
2008. Effects of a reduced dose schedule and intramuscular administra-
tion of anthrax vaccine adsorbed on immunogenicity and safety at 7
months: a randomized trial. JAMA 300:1532–1543.
10. Wright JG, Quinn CP, Shadomy S, Messonnier N. 2010. Use of anthrax
vaccine in the United States: recommendations of the Advisory Commit-
tee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep.
59(RR-6):1–30.
11. Crowe SR, Garman L, Engler RJ, Farris AD, Ballard JD, Harley JB,
James JA. 2011. Anthrax vaccination induced anti-lethal factor IgG: fine
specificity and neutralizing capacity. Vaccine 29:3670 –3678.
12. Pajewski NM, Shrestha S, Quinn CP, Parker SD, Wiener H, Aissani B,
McKinney BA, Poland GA, Edberg JC, Kimberly RP, Tang J, Kaslow
RA. 2012. A genome-wide association study of host genetic determinants
of the antibody response to Anthrax Vaccine Adsorbed. Vaccine 30:4778 –
4784.
13. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA,
Fernandez-Vina M, Geraghty DE, Holdsworth R, Hurley CK, Lau M,
Lee KW, Mach B, Maiers M, Mayr WR, Muller CR, Parham P, Peters-
dorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy
JM, Trowsdale J. 2010. Nomenclature for factors of the HLA system,
2010. Tissue Antigens 75:291– 455.
14. Pajewski NM, Parker SD, Poland GA, Ovsyannikova IG, Song W,
Zhang K, McKinney BA, Pankratz VS, Edberg JC, Kimberly RP, Jacob-
son RM, Tang J, Kaslow RA. 2011. The role of HLA-DR-DQ haplotypes
in variable antibody responses to anthrax vaccine adsorbed. Genes Im-
mun. 12:457– 465.
15. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL,
Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R,
Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM,
Plikaytis BD, Marano N. 2012. A three dose intramuscular schedule of
Anthrax Vaccine Adsorbed generates sustained humoral and cellular im-
mune responses to protective antigen and provides long term protection
against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol.
19:1730 –1745.
16. Ovsyannikova IG, Ryan JE, Vierkant RA, O’Byrne MM, Jacobson RM,
Poland GA. 2009. Influence of host genetic variation on rubella-specific T
cell cytokine responses following rubella vaccination. Vaccine 27:3359 –
3366.
17. Ovsyannikova IG, Jacobson RM, Ryan JE, Vierkant RA, Pankratz VS,
Jacobsen SJ, Poland GA. 2005. HLA class II alleles and measles virus-
specific cytokine immune response following two doses of measles vac-
cine. Immunogenetics 56:798 – 807.
18. Ovsyannikova IG, Jacobson RM, Vierkant RA, O’Byrne MM, Poland
GA. 2009. Replication of rubella vaccine population genetic studies: vali-
dation of HLA genotype and humoral response associations. Vaccine 27:
6926 – 6931.
19. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz
VS, Poland GA. 2004. The contribution of HLA class I antigens in im-
mune status following two doses of rubella vaccination. Hum. Immunol.
65:1506 –1515.
20. Ovsyannikova IG, Poland GA, Easler NJ, Vierkant RA. 2004. Influence
of HLA-DRB1 alleles on lymphoproliferative responses to a naturally pro-
cessed and presented measles virus phosphoprotein in measles immu-
nized individuals. Hum. Immunol. 65:209 –217.
21. Ovsyannikova IG, Vierkant RA, Pankratz VS, O’Byrne MM, Jacobson
RM, Poland GA. 2009. HLA haplotype and supertype associations with
cellular immune responses and cytokine production in healthy children
after rubella vaccine. Vaccine 27:3349 –3358.
22. St Sauver JL, Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA,
Pankratz SV, Jacobsen SJ, Poland GA. 2005. Extinction of the human
leukocyte antigen homozygosity effect after two doses of the measles-
mumps-rubella vaccine. Hum. Immunol. 66:788 –798.
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. 2002.
Score tests for association between traits and haplotypes when linkage
phase is ambiguous. Am. J. Hum. Genet. 70:425– 434.
24. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. 2007. Hetero-
geneity in vaccine immune response: the role of immunogenetics and the
emerging field of vaccinomics. Clin. Pharmacol. Ther. 82:653– 664.
25. Pati NT, Sukriti Hissar S, Agrawal K, Rani R, Sarin SK. 2007. Decrease
in CD4 T lymphocyte proliferation responses and enhanced CD150 cell
expression in health care workers non-responsive to HBV vaccine. Vac-
cine 25:1848 –1855.
26. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA.
2004. HLA and cytokine gene polymorphisms are independently asso-
ciated with responses to hepatitis B vaccination. Hepatology 39:978 –
988.
27. Mustafa AS, Lundin KE, Oftung F. 1993. Human T cells recognize
mycobacterial heat shock proteins in the context of multiple HLA-DR
molecules: studies with healthy subjects vaccinated with Mycobacte-
rium bovis BCG and Mycobacterium leprae. Infect. Immun. 61:5294 –
5301.
28. Kwok WW, Yang J, James E, Bui J, Huston L, Wiesen AR, Roti M. 2008.
The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-
specific CD4 T cells with a phenotype distinct from that of naive PA T
cells. Infect. Immun. 76:4538 – 4545.
29. Ingram RJ, Metan G, Maillere B, Doganay M, Ozkul Y, Kim LU, Baillie
L, Dyson H, Williamson ED, Chu KK, Ascough S, Moore S, Huwar TB,
Robinson JH, Sriskandan S, Altmann DM. 2010. Natural exposure to
cutaneous anthrax gives long-lasting T cell immunity encompassing in-
fection-specific epitopes. J. Immunol. 184:3814 –3821.
30. Davila J, McNamara LA, Yang Z. 2012. Comparison of the predicted
population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6,
Ag85B-TB10.4, and Mtb72f via a bioinformatics approach. PLoS One
7:e40882. doi:10.1371/journal.pone.0040882.
31. Hraber PT, Kuiken C, Yusim K. 2007. Evidence for human leukocyte
antigen heterozygote advantage against hepatitis C virus infection. Hepa-
tology 46:1713–1721.
32. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert
JJ, Kaslow R, Buchbinder S, Hoots K, O’Brien SJ. 1999. HLA and HIV-1:
heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:
1748 –1752.
33. Tang JM, Costello C, Keet IPM, Rivers C, LeBlanc S, Karita E, Allen S,
Kaslow RA. 1999. HLA class I homozygosity accelerates disease progres-
sion in human immunodeficiency virus type I infection. AIDS Res. Hum.
Retroviruses 15:317–324.
34. Thursz MR, Thomas HC, Greenwood BM, Hill AVS. 1997. Heterozy-
gote advantage for HLA class-II type in hepatitis B virus infection. Nat.
Genet. 17:11–12.
35. Seppänen M, Lokki ML, Timonen T, Lappalainen M, Jarva H, Jarvinen
A, Sarna S, Valtonen V, Meri S. 2001. Complement C4 deficiency and
HLA homozygosity in patients with frequent intraoral herpes simplex
virus type 1 infections. Clin. Infect. Dis. 33:1604 –1607.
36. Burgner D, Jamieson SE, Blackwell JM. 2006. Genetic susceptibility to
infectious diseases: big is beautiful, but will bigger be even better? Lancet
Infect. Dis. 6:653– 663.
37. St Sauver JL, Ovsyannikova IG, Jacobson RM, Jacobsen SJ, Vierkant
RA, Schaid DJ, Pankratz VS, Green EM, Poland GA. 2002. Associations
between human leukocyte antigen homozygosity and antibody levels to
measles vaccine. J. Infect. Dis. 185:1545–1549.
38. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink
SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of nonre-
sponse to hepatitis B vaccine. N. Engl. J. Med. 321:708 –712.
39. Jacobson RM, Ovsyannikova IG, Vierkant RA, Shane P, Poland VGA.
Ovsyannikova et al.
2590 iai.asm.org Infection and Immunity
 
 
2011. Human leukocyte antigen associations with humoral and cellular
immunity following a second dose of measles-containing vaccine: persis-
tence, dampening, and extinction of associations found after a first dose.
Vaccine 29:7982–7991.
40. Kennedy RB, Ovsyannikova IG, Vierkant RA, Jacobson RM, Poland
GA. 2010. Effect of human leukocyte antigen homozygosity on rubella
vaccine-induced humoral and cell-mediated immune responses. Hum.
Immunol. 71:128 –135.
41. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin.
Vaccine Immunol. 17:1055–1065.
42. Quinn CP, Sabourin CL, Mittler R, Wrammert J, Schiffer J, Li H, Se-
menova V, Parker S, Babcock J, Keitel W, Poland GA, Keyserling H,
Plikaytis B, Wright J. 2010. Humoral antibody and immune cell responses to
reduced schedules of anthrax vaccine absorbed in humans, abstr 104(H), p 67.
Program and abstracts of the ASM Biodefense and Emerging Diseases Re-
search Meeting. American Society for Microbiology, Washington, DC.
HLA and Anthrax Vaccine Adsorbed Cellular Immunity
July 2013 Volume 81 Number 7 iai.asm.org 2591
 
SUPPLEMENTAL TABLE 1.   HLA homozygosity associations with antibody responses to 
anthrax protective antigen 
Parameter Level N 
Median 
(IgG, 
µg/ml) Q1 Q3 P-value 
HLA Locus       
A (4 digit) Heterozygous 229 236.0 121.0 390.9 0.199 
 Homozygous 42 215.2 84.3 361.7  
       
B (4 digit) Heterozygous 255 226.8 113.6 381.1 0.518 
 Homozygous 16 260.9 144.7 435.7  
       
C (4 digit) Heterozygous 246 225.7 110.5 381.1 0.404 
 Homozygous 25 288.2 178.0 418.0  
       
DRB1 (4 digit) Heterozygous 245 228.3 116.9 388.6 0.866 
 Homozygous 26 217.9 104.6 323.4  
       
DPA1 (4 digit) Heterozygous 101 242.2 119.6 451.3 0.500 
 Homozygous 170 222.6 113.6 362.4  
       
DQA1 (4 digit) Heterozygous 221 224.6 111.3 391.6 0.904 
 Homozygous 50 235.4 141.6 362.6  
       
DPB1 (4 digit) Heterozygous 211 236.0 107.4 391.6 0.741 
 Homozygous 60 219.4 118.6 381.9  
       
DQB1 (4 digit) Heterozygous 229 237.6 118.4 406.1 0.259 
 Homozygous 42 207.0 101.7 311.3  
       
Any Locus (4 digit) Heterozygous 69 260.2 132.5 451.3 0.109 
 Homozygous 202 222.6 110.5 362.6  
       
Number Homozygous (4 digit) 0 69 260.2 132.5 451.3 0.413 
 1 81 208.9 101.9 347.9  
 2 68 233.2 146.4 428.3  
 3 25 203.6 101.4 314.6  
 4+ 28 213.1 120.4 317.4  
       
       
A (2 digit) Heterozygous 228 236.7 120.3 391.3 0.181 
 Homozygous 43 214.9 84.3 361.7  
       
B (2 digit) Heterozygous 250 227.6 113.6 381.1 0.325 
 Homozygous 21 233.5 124.4 399.2  
       
C (2 digit) Heterozygous 234 223.0 110.5 382.7 0.265 
 Homozygous 37 258.0 178.0 399.2  
       
DRB1 (2 digit) Heterozygous 229 237.6 119.5 391.7 0.028 
 Homozygous 42 180.5 82.6 311.3  
       
DPA1 (2 digit) Heterozygous 90 236.5 107.4 456.9 0.758 
 Homozygous 181 224.2 116.9 362.4  
       
DQA1 (2 digit) Heterozygous 186 235.9 116.9 413.3 0.082 
 Homozygous 85 223.4 105.9 328.3  
       
DPB1 (2 digit) Heterozygous 185 242.2 111.3 409.7 0.669 
 Homozygous 86 215.8 116.2 348.2  
       
DQB1 (2 digit) Heterozygous 181 242.2 119.5 406.1 0.153 
 Homozygous 90 220.7 110.5 319.8  
       
Any Locus (2 digit) Heterozygous 44 259.0 113.5 464.0 0.329 
 Homozygous 227 224.6 113.6 370.7  
       
Number Homozygous (2 digit) 0 44 259.0 113.5 464.0 0.056 
 1 57 260.6 106.9 413.3  
 2 78 235.9 141.6 380.5  
 3 39 214.9 110.5 381.1  
 4+ 53 215.5 104.6 314.6  
 
P-values values for antibody levels were based on analyses using a logarithmic transformation. 
Statistically significant P-values are in bold type (P < 0.05). Linear regression analysis adjusted 
for gender, age groups, study site, route of immunization, time between vaccination, time 
between blood draw and a number of AVA doses. 
 
